Reviews of "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

Kabir Biswas; Kimberly Luke; Geraldo Passos; Binquan Luan; Haoran Wang

doi:doi:10.1162/2e3983f5.795a21cd

SearchLogin or Signup

Reviews of "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

Reviewers: Kabir Biswas (Hamad Bin Khalifa University) | 📘📘📘📘📘 • Kimberly Luke (Intuitive Biosciences) | 📒📒📒◻️◻️ • Geraldo Passos (University of Sao Paulo) | 📗📗📗📗◻️ • Binquan Luan (IBM T J Watson Research), Haoran Wang (Neoland Bioscience) | 📘📘📘📘📘

by Kabir Biswas, Kimberly Luke, Geraldo Passos, Binquan Luan, and Haoran Wang

Published onFeb 07, 2021

This Pub is a Review of

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

by Xuping Xie, Jing Zou, Camila R. Fontes-Garfias, Hongjie Xia, Kena A. Swanson, Mark Cutler, David Cooper, Vineet D. Menachery, Scott Weaver, Philip R. Dormitzer, and Pei-Yong Shi

Show Description
dx.doi.org

Description

AbstractRapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.

To read the original manuscript, click the link above.

Summary of Reviews: This preprint showed data that BNT162b2 vaccine may protect against a spike mutation associated with rapidly spreading SARS-CoV-2 strains, but more work needs to be done.

Reviewer 1 (Kabir Biswas) | 📘📘📘📘📘

Reviewer 2 (Kimberly Luke) | 📒📒📒◻️◻️

Reviewer 3 (Geraldo Passos) | 📗📗📗📗◻️

Reviewer 4 (Binquan Luan, Haoran Wang) | 📘📘📘📘📘

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below.

Connections

1 of 4

A Supplement to this Pub

Review 1: "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

by Kabir Biswas

Show Description
Published on Feb 07, 2021
rapidreviewscovid19.mitpress.mit.edu

Description

This preprint showed data that BNT162b2 vaccine may protect against a spike mutation associated with rapidly spreading SARS-CoV-2 strains, but more work needs to be done.

A Supplement to this Pub

Review 2: "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

by Kimberly Luke

Show Description
Published on Feb 07, 2021
rapidreviewscovid19.mitpress.mit.edu

Description

This preprint showed data that BNT162b2 vaccine may protect against a spike mutation associated with rapidly spreading SARS-CoV-2 strains, but more work needs to be done.

A Supplement to this Pub

Review 3: "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

by Geraldo Passos

Show Description
Published on Feb 07, 2021
rapidreviewscovid19.mitpress.mit.edu

Description

This preprint showed data that BNT162b2 vaccine may protect against a spike mutation associated with rapidly spreading SARS-CoV-2 strains, but more work needs to be done.

A Supplement to this Pub

Review 4: "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

by Binquan Luan and Haoran Wang

Show Description
Published on Feb 07, 2021
rapidreviewscovid19.mitpress.mit.edu

Description

This preprint showed data that BNT162b2 vaccine may protect against a spike mutation associated with rapidly spreading SARS-CoV-2 strains, but more work needs to be done.

License

Creative Commons Attribution 4.0 International License (CC-BY 4.0)

Comments

Reviews of "Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera"

Connections

No comments here